Unit Dose Form of Glufosfamide
OwnerMike Liinventor
Life of this patent
Estimating the term…
Abstract
A lyophilized unit dose form containing about 2 g of glufosfamide is useful in treatment of cancer and other hyper-proliferative diseases.
Claims12
A lyophilized unit dose form comprising at least about 2 g of glufosfamide API.
A method of producing a lyophilized unit dose form comprising about 2 g of glufosfamide, the method comprising the steps of:
- (a) annealing a solution of about 2 g glufosfamide and an aqueous solvent at a temperature of about Ta and for a time of about θa;
- (b) conducting a first primary drying, at a vacuum of about V1, a temperature of about T1a, and for a time of about θ1a. the frozen mixture annealed in step (a);
- (c) conducting a second primary drying, at a vacuum of about V1, a temperature of about T1b wherein T1b>T1a, and for a time of about θ1b, the frozen mixture first primary dried in step (b);
- and
- (d) conducting a secondary drying, at a vacuum of about V2, a temperature of about T2 wherein T2>T1b, and for a time of about θ2, the frozen mixture second primary dried in step (c)
- wherein, Ta is about 0° C. and θa is about 18 h;
- V1 is from about 120 microns to about 180 microns, T1a is about −20° C., θ1a is about 72 h, T1b is about 0° C., θ1b is about 38 h;
- and V2 is about 70 microns, T2 is about 25° C., and θ2 is about 24 h.
A method of treating cancer, said method comprising dissolving a lyophilized unit dose form comprising about 2 g of glufosfamide in a pharmaceutically acceptable solvent to yield a pharmaceutically acceptable solution of glufosfamide and administering the pharmaceutically acceptable solution of glufosfamide to a patient in need of such therapy.
Dependencies are inferred from the claim text.